Pavilion Health Today
Supporting healthcare professionals to deliver the best patient care

The role of SGLT2 inhibitors in Type 2 Diabetes

The advent of SGLT2 inhibitors, a new class of glucose lowering agent, currently represented by dapagliflozin (Forxiga)and canagliflozin (Invokana), offers a new mechanistic paradigm for treatment. Here, the authors consider the prescribing rationale and precautions, with an emphasis on the pharmacodynamic and kinetic properties of these agents.

The advent of SGLT2 inhibitors, a new class of glucose lowering agent, currently represented by dapagliflozin (Forxiga)and canagliflozin (Invokana), offers a new mechanistic paradigm for treatment. Here, the authors consider the prescribing rationale and precautions, with an emphasis on the pharmacodynamic and kinetic properties of these agents. Andrew V Bailey Clinical Pharmacist, DIMEC, Med IC 4, Keele University Science Park Caroline Day Visiting Fellow, School of Life and Health Sciences, Aston University, Birmingham Background  Costing about 11% of global healthcare budgets, diabetes currently affects an estimated 382 million adults worldwide, a figure that is expected to escalate above 590 million

---------------------------

This content is restricted to members of Pavilion Health Today. If you are an existing user, please log in. New users may register for free below.

Existing Users Log In
   
New User Registration
captcha
*Required field

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more ...

Privacy & Cookies Policy